INIFY Laboratories AB
OOSL:INIFY5.85
NOK
0.00
(0.00%)
ISIN
SE0017486103
Return %
Stock
S&P 500
1Y
-4.88
14.20
3Y
-55.26
81.12
5Y
- -
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Fredrik Palm
- Full Time Employees
- 38
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Solna Sweden
- IPO Date
- Jun 20, 2022
- Website
- inify.com
- Similar Companies
- Business
- INIFY Laboratories AB is a Sweden-based medical technology company that provides digital pathology laboratory services and artificial intelligence-assisted diagnostic solutions for cancer detection. The company operates a fully integrated, digitized histopathology workflow designed to optimize diagnostic turnaround times, accuracy, and standardization for healthcare providers. Its core service offerings and solutions include end-to-end prostate cancer biopsy diagnostics; gastrointestinal histopathology analysis; proprietary AI-driven image analysis and clinical decision-support software for pathologists; automated tissue processing, embedding, sectioning, and staining services; high-throughput whole-slide digital imaging; and structured visual pathology reporting and remote subspecialty consultation services. INIFY Laboratories caters primarily to public health authorities, regional hospital trusts, private medical centers, and outpatient urology clinics across Sweden and the United Kingdom. Founded in 2022 as an independent spin-off from ContextVision AB, the company is headquartered in Solna, Sweden, and trades on Euronext Growth Oslo under the ticker symbol INIFY. In recent operational and strategic developments, INIFY Laboratories expanded its geographic footprint into the United Kingdom by establishing and commissioning a dedicated pathology facility at Milton Park in Oxfordshire after obtaining registration with the Care Quality Commission. The company expanded its diagnostic portfolio beyond urology to launch specialized gastrointestinal pathology services. Strategically, INIFY has entered into several clinical and research collaborations, including a diagnostic services agreement with University Hospitals Plymouth NHS Trust to accelerate prostate cancer testing pathways, patient diagnostic work with Parkside Frimley, and a precision cancer diagnostics research partnership with the Karolinska Institutet Department of Molecular Medicine and Surgery. To support international expansion and infrastructure development, the company completed a private placement and repair issue raising approximately NOK 100 million in late 2025, following a SEK 150 million capital raise in late 2024, and secured medical laboratory accreditation enabling broader participation in national public healthcare procurement frameworks.